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Abstract: Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is FDA 
approved for the treatment of generalized anxiety disorder (GAD) in doses of 30 mg to 120 mg 
daily. Duloxetine has been shown to significantly improve symptoms of GAD as measured 
through the Hamilton Anxiety Rating Scale (HAMA), the Clinical Global Impressions Scale 
(CGI-I), and other various outcome measures in several placebo-controlled, randomized, 
double blind, multi-center studies. Symptom improvement began within the first few weeks, 
and continued for the duration of the studies. In addition, duloxetine has also been shown to 
improve outcomes in elderly patients with GAD, and in GAD patients with clinically significant 
pain symptoms. Duloxetine was noninferior compared with venlafaxine XR. Duloxetine was 
found to have a good tolerability profile which was predictable and similar to another SNRI, 
venlafaxine. Adverse events (AEs) such as nausea, constipation, dry mouth, and insomnia were 
mild and transient, and occurred at relatively low rates. It was found to have a low frequency of 
drug interactions. In conclusion, duloxetine, a selective inhibitor for the serotonin and norepi-
nephrine transporters, is efficacious in the treatment of GAD, and has a predictable tolerability 
profile, with AEs generally being mild to moderate.
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Introduction
Generalized anxiety disorder (GAD) is a serious and potentially debilitating psychiatric 
disorder characterized by generalized and persistent excessive anxiety, accompa-
nied by other psychological or somatic symptoms (eg, palpitations, sweating, sleep 
disturbances).1,2 Symptoms for GAD diagnosis, which must be present for at least 
6 months (according to DSM–IV and ICD-10 criteria) can be found in Table 1.
GAD is a common disorder, with a lifetime and 12-month prevalence in the US 
of 4.1% and 2.1%, respectively.3 In Europe, the lifetime prevalence was found to 
be similar at 4.3% to 5.9%.2 GAD often coexists with other psychiatric disorders, 
such as major depressive disorder (MDD), panic disorder (PD), or alcohol and sub-
stance abuse.1 The most common of these psychiatric comorbidities is MDD which 
is observed in almost two thirds of patients.4 As well as psychiatric comorbidities, 
GAD is also comorbid with a number of medical conditions including cardiovas-
cular disease, stroke, peptic ulcer disease, irritable bowel syndrome, pain, and 
headache.1 The high prevalence of GAD and its comorbid conditions results in a 
substantial financial burden as well as a personal one. In fact, some estimates put 
the US economic cost of anxiety disorders, inclusive of GAD, at US$42 to US$63 
billion per year.5,6 A recent retrospective review of healthcare claims in patients International Journal of General Medicine 2009:2 154
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with GAD found an average annual cost of US$7,451 per 
patient, and that 77% of these patients had either comorbid 
pain or depression.7 The disease is almost twice as common 
in women than men, generally appears in childhood or late 
adolescence, and has a median duration of 15.6 years;8 
however it can appear later in life, and is often precipitated 
by a life-changing event.8
It is hypothesized that GAD is the result of  neurobio-
logical dysfunction of the serotonergic, noradrenergic, or 
GABAergic systems,2 and medications that have an effect 
on these systems are able to reduce GAD symptoms.9 The 
use of buspirone, selective serotonin (5-HT) reuptake 
inhibitor (SSRI) antidepressants and/or benzodiazepines 
are commonly prescribed as first-line agents in treating GAD, 
followed by serotonin/norepinephrine reuptake inhibitor 
(SNRI) antidepressants, mirtazapine, or a monoamine 
oxidase inhibitor (MAOI). If unsuccessful with these 
medications, tricyclic antidepressants, anticonvulsants, 
and antipsychotics may be used.4,7,8,10,11 Psychotherapy, as 
monotherapy or combined with pharmacotherapy, has also 
been studied to treat GAD.12 Psychotherapeutic approaches 
include cognitive behavioral therapy, psychodynamic 
therapy, and supportive therapy.12
Currently, there are two SNRIs approved by the FDA 
for the treatment of GAD – venlafaxine and, more recently, 
duloxetine. This article will review the efficacy of the SNRI 
duloxetine in the treatment of GAD.
Duloxetine
Pharmacodynamics
Duloxetine is a SNRI that is approved by the FDA for the 
treatment of MDD, neuropathic pain, fibromyalgia, and 
GAD.13 Its mechanism of action is based upon reuptake 
inhibition of 5-HT and norepinephrine (NE) in the CNS.14 
A number of in vitro experiments show that duloxetine has 
good affinity for 5-HT and NE transporters, and is able to 
decrease 5-HT and NE uptake,15–17 Other preclinical studies 
demonstrate the low affinity that duloxetine has for other 
transporters (DA, GABA)18 and for other neuronal binding 
sites (monoamine receptor subtypes and ion channels).15 
In addition to in vitro studies, various in vivo techniques have 
been used to demonstrate duloxetine’s inhibitory capabilities 
at 5-HT and NE transporters.15,16
There are also a number of clinical studies which 
demonstrate the ability of duloxetine to inhibit reuptake of 
NE and 5-HT.14 Reuptake inhibition of 5-HT can be shown 
by the use of platelet 5-HT levels. Platelets have a similar 
mechanism of 5-HT reuptake to that found in the CNS, and 
therefore 5-HT levels in the blood depend on the extent of 
reuptake inhibition in platelets. Turcotte et al and Chalon 
et al have demonstrated this relationship by showing an 
increase in blood 5-HT levels using duloxetine doses of 
20 mg daily to 120 mg daily.19,20 Since there is no direct 
measure of NE reuptake inhibition, of NE activity is assessed 
by measuring the amount of NE and NE metabolites in the 
urine, cardiovascular effects NE reuptake inhibition, and by 
reduction of pain symptoms and adverse drug effects from 
NE reuptake inhibition.14 Each of these methods has been 
used to successfully demonstrate the ability of duloxetine 
to inhibit NE reuptake.14
Pharmacokinetics
After a single 20.2 mg dose of oral duloxetine, the mean time 
to peak plasma concentration (Cmax) is 6 hours.21 During 
a dose escalation study, 8 subjects received duloxetine 20 mg 
twice daily, 30 mg twice daily then 40 mg twice daily. Steady 
state plasma concentrations were reached after 5 days and 
duloxetine has a mean half-life of 12.5 hours22 (with a range 
of 8 to 17 hours);13 thus duloxetine is a suitable candidate for 
once daily dosing. In the same study, duloxetine was shown 
to follow first-order absorption and elimination kinetics, and 
have a mean oral clearance of 114 L/hour, and mean apparent 
volume of distribution of 1943 L.21 Absorption of duloxetine 
is unaffected by food,13 which makes dosing convenient and 
aids medication adherence.
Duloxetine is greater than 90% plasma protein bound, so 
caution should be exercised when administered with other 
highly protein bound drugs such as warfarin or phenytoin.13 
It is extensively metabolized by the liver via CYP1A2 and 
CYP2D613 resulting in various metabolites, the most pre-
dominant of these being the glucuronide conjugate 4-hydroxy 
duloxetine.21 Its metabolism by the cytochrome P450 system 
leads to the potential of certain drug interactions, as discussed 
in the next section. None of the duloxetine metabolites appear 
to be pharmacologically active.13 Excretion occurs 72% via 
the kidneys and 19% via feces.21
Table 1 Symptoms of generalized anxiety disorder1
Psychological symptoms Physical symptoms
excessive anxiety Fatigue
Inability to control worries restlessness
Difficulty concentrating Muscle tension
Feeling “on edge” Nausea and diarrhea
Palpitations
  SweatingInternational Journal of General Medicine 2009:2 155
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Drug–drug interactions
Because of its metabolism by 1A2 and 2D6, there is a 
potential for drug interactions to take place between dulox-
etine and inhibitors, inducers, or substrates of these enzymes. 
When duloxetine 60 mg was co-administered with fluvox-
amine 100 mg (a 1A2 inhibitor) as a single dose, the result 
was an approximately 6-fold increase in duloxetine AUC, 
2.5-fold increase in Cmax, and a 3-fold increase in half-life.13 
In another study, duloxetine 40 mg daily at steady state 
conditions was co-administered with paroxetine 20 mg 
(a potent 2D6 inhibitor). Pharmacokinetic analysis showed 
a 1.6-fold increase in both duloxetine AUC and Cmax.23 
Duloxetine has been reported to have a small inhibitory effect 
on CYP1A2, but no effect on 2C9, 2C19 or 3A4.13,24 It has, 
however, been shown to have a significant inhibitory effect 
on CYP2D6. Thirteen subjects each received desipramine 
50 mg (a substrate for CYP2D6) after 21 days of duloxetine 
therapy. It was found that desipramine Cmax had increased 
1.7-fold, and AUC had increased 2.9-fold.23 Another potential 
drug interaction involves the use of anticoagulants (owing 
to the small 1A2 inhibition).25 Pharmacodynamic drug 
interactions may occur with MAOIs, and other serotonergic 
drugs, resulting in an increased risk of serotonin syndrome. 
An example of this involved an interaction between 
duloxetine and linezolid. Linezolid has been shown to be a 
nonselective inhibitor of monoamine oxidase.26 It is recom-
mended that patients be monitored closely if taking dulox-
etine concomitantly with any of these drug classes.13
Efficacy in GAD
A Medline search was made using the keywords duloxetine, 
Cymbalta®, generalized/generalised anxiety disorder, efficacy, 
and controlled trial. Five controlled trials for the use of 
duloxetine in GAD were found. The following section will 
summarize these trials.
Koponen et al carried out a multicenter, randomized, 
double blind, fixed-dose, placebo-controlled trial.27 Study 
sites were located in the US, Europe, and South Africa. 
The study was a 9-week treatment phase followed by a 
2-week discontinuation phase. All subjects participated in 
a pretreatment screening phase and washout period, and a 
1-week single-blind placebo lead in phase. Subjects were 
diagnosed with GAD by a psychiatrist via the use of the 
Mini-International Neuropsychiatric Interview (MINI) and 
according to DSM-IV criteria. Subjects were excluded from 
the trial if the patient suffered from significant comorbidities 
or other mental disorders such as a recent diagnosis of  MDD, 
substance abuse, post-traumatic stress disorder (PTSD), panic 
disorder, eating disorder, bipolar, obsessive compulsive 
disorder, or psychosis. Subjects were randomly assigned one 
of two active treatment groups: 60 mg duloxetine daily, or 
120 mg duloxetine daily, along with a placebo group. The 
mean total Hamilton Rating Scale for Anxiety (HAM-A) 
scores at baseline were approximately 25 in all 3 groups, 
indicating moderately severe GAD.
The primary efficacy outcome measure was defined 
as a 50% reduction in total HAM-A score from base-
line, and sustained improvement rates were defined as 
a 30% reduction in total HAM-A score from baseline 
to the last visit. Remission was defined as a 7 HAM-
A total score at endpoint. Secondary outcome measures 
were scores on the HAM-A psychic factor, the HAM-A 
somatic factor, the patient reported Hospital Anxiety and 
Depression Scale (HADS), the Clinical Global Impressions-
Improvement scale (CGI-I), the Patient Global Impressions-
Improvement scale (PGI-I), and the Sheehan Disability Scale 
(used to rate social, family, and work impairment).
Both treatment arms reported a significantly greater 
decrease in total HAM-A score as compared to placebo. 
The mean change from baseline was -12.8 in the 60 mg 
group, -12.5 in the 120 mg group, and -8.38 in the placebo 
group (P  0.001 for both groups vs placebo). (Standard 
deviations were not reported). This corresponded to a mean 
decrease in total HAM-A score of 49% in duloxetine treated 
patients. A response was achieved by 58% of the dulox-
etine 60 mg group, 56% of the duloxetine 120 mg group, 
and 31% of the placebo group (P  0.001 both groups 
vs placebo), and remission was achieved by 31%, 38%, 
and 19% of the duloxetine 60 mg, 120 mg, and placebo 
groups, respectively (P  0.01 for duloxetine 60 mg vs 
placebo; P  0.001 for duloxetine 120 mg vs placebo). 
The duloxetine groups also had significantly greater sus-
tained improvement rates as compared with the placebo 
group -64% and 67% for the 60 mg and 120 mg groups 
respectively, vs 43% for placebo (P  0.001 both groups 
vs placebo). Secondary outcome measures also showed 
a greater improvement in the duloxetine groups over the 
placebo group (Table 2).
A similar study was completed by Rynn et al28 and with 
the same primary and secondary endpoints as Koponen et al.27 
However, this study was conducted at sites exclusively in 
the US and consisted of a 10 week-long therapy phase rather 
than 9 weeks. Also, this study involved a titrated duloxetine 
dose as opposed to a fixed dose. All subjects participated 
in a pre-treatment screening phase and washout period, 
and a 1-week, single-blind placebo lead in phase. Subjects International Journal of General Medicine 2009:2 156
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were randomly assigned to either an active treatment group, 
dosed at 60 to 120 mg duloxetine daily, or a placebo group. 
Patients began taking 60 mg duloxetine daily. After 2 weeks 
of treatment, and if tolerated, this dose was titrated upwards 
(in 30-mg increments) to a maximum of 120 mg daily, if 
the subject’s CGI-I rating was 3 (signifying little, or no 
improvement). Baseline total HAM-A scores were approxi-
mately 22.6 ± 7.4 for the duloxetine group, and 23.5 ± 7.9 
for the placebo group.
The mean dose taken by the active duloxetine group was 
101.94 mg/day (18.23% at 60 mg/day, 23.66% at 90 mg/day, 
and 58.06% at 120 mg/day). The duloxetine treatment 
arm experienced a greater decrease in total HAM-A score 
compared to placebo where the mean change from baseline 
was -8.12 vs -5.89 for placebo (P = 0.023) (standard 
deviations were not reported). This corresponded to a mean 
decrease in total HAM-A score of 36% in duloxetine-treated 
patients. A response was achieved by 40% of the dulox-
etine group, and 32% of the placebo group (P  0.05), and 
remission was achieved by 28% and 23% of the duloxetine 
and placebo groups, respectively (NS, P = 0.27). Sustained 
improvement rates were significantly greater for the dulox-
etine group compared to placebo, being 43.7% and 32%, 
respectively (P  0.05). Secondary outcome measures also 
showed a greater improvement in the duloxetine group over 
the placebo group.
Two studies carried out by Hartford et al29 and Nicolini 
et al30 looked at the efficacy of duloxetine and venlafaxine 
XR (venlafaxine extended release) for the treatment of 
GAD. Individually, these studies were not powered to draw 
a direct comparison between duloxetine and venlafaxine 
XR, but when pooled together, a noninferiority analysis 
could be done. Both studies were multicenter, randomized, 
double-blind, parallel-group, placebo-controlled studies 
conducted at various sites in North and South America, 
Europe, Australia, Russia, and Taiwan. Both consisted of a 
10-week treatment period where subjects were randomized 
to receive either duloxetine, venlafaxine XR or placebo. 
Subject diagnosis with GAD, primary and secondary out-
comes, and exclusion/inclusion criteria were the same as for 
the Koponen27 and Rynn28 studies.
For Hartford et al subjects were randomly assigned to 
receive either titration-based duloxetine 60 to 120 mg/day, 
venlafaxine XR 75 to 225 mg/day, or placebo. For Nicolini 
et al subjects were randomized to receive duloxetine 
20 mg/day, duloxetine 60 to 120 mg/day, venlafaxine 
XR 75 to 225 mg/day, or placebo (n = 170) (the duloxetine 
20 mg daily dose was fixed and was included to satisfy 
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European regulatory requirements). For both studies, the 
duloxetine group daily dose was titrated in 30-mg increments 
to a maximum of 120 mg daily, if tolerated. The venlafaxine 
group’s doses were titrated from 75 mg daily up to a 
maximum of 225 mg daily, if tolerated. Doses were increased 
if there was no improvement in CGI-I score (ie, 3).
At endpoint, the mean duloxetine doses being taken were 
107.73 mg/day for Hartford et al and 90 mg/day for Nicolini 
et al. The duloxetine treatment arms experienced a greater 
decrease in total HAM-A score compared to placebo. The 
mean changes from baseline in the duloxetine 60 to 120 mg 
groups were -11.8 ± 0.69(SE) for the Hartford et al study, 
and -15.3 ± 0.7(SE) for the Nicolini et al study, which 
corresponds to mean decreases in HAM-A of 46% and 
55%, respectively. The duloxetine 20 mg group from the 
Nicolini et al study saw a HAM-A decrease of 14.7 ± 1.0 (SE) 
corresponding to a mean decrease of 45%. All changes were 
statistically significant vs placebo. Efficacy and demographic 
data for the 4 studies discussed previously is summarized 
in Table 2.
In addition to the 4 acute clinical trials, a relapse 
prevention study of duloxetine in GAD was conducted.31 The 
study determined the relapse rate of GAD after discontinua-
tion of duloxetine, and was a randomized, double blind, 
placebo-controlled trial, conducted at sites throughout the 
US and Europe. It consisted of a 26-week open label phase 
where 887 patients were enrolled to take duloxetine 60 to 
120 mg daily. This was done in a flexible dosing manner, 
whereby doses were increased from 60 mg to 120 mg daily 
if patients were non responsive (defined as a CGI-I  3) and 
if medication could be tolerated. If subjects were responsive 
to their medication (defined as a 50% reduction in HAM-
A total score from baseline) they were randomized into the 
double-blind, placebo-controlled continuation phase of the 
study. Subjects who were randomized to receive placebo 
had their duloxetine dose tapered over a 2-week period. The 
primary efficacy measure for this trial was time to relapse, 
with relapse defined by a 2 point increase on the CGI-S 
scale and a score of 4. Secondary measures were similar 
to the previous studies, and included HAM-A total score, 
HADS, and SDS. Out of the 887 subjects in the open label 
phase, 429 were randomized to take part in the continua-
tion phase. Reasons for subject discontinuation included 
inadequate response during open label phase (9.7%), adverse 
events (AEs) (13.6%) and patient decision (12%). Subjects 
remaining were assigned to either duloxetine (continued at 
the same dose as during the open-label phase) or placebo 
for 26 weeks.
Results showed that duloxetine was superior to placebo in 
preventing relapse of GAD over the 26-week period. Relapse 
criteria was met by 13.7% of the duloxetine group compared 
to 41.8% of the placebo group (P  0.001), and the mean 
change in HAM-A score from baseline was 7.5 ± 0.6 (SE) 
for the placebo group vs 1.6 ± 0.6 (SE) for the active group 
(P  0.001). For the patients who did relapse, those treated 
with placebo relapsed at an earlier time period than those 
treated with duloxetine (P  0.001).
Special patient populations
Using pooled data from previous studies the use of dulox-
etine was analyzed in specific patient populations. An 
analysis of duloxetine efficacy in treating GAD patients 
with clinically significant pain symptoms was conducted by 
Russell et al32 Data was pooled from the studies completed 
by Koponen et al27 and Rynn et al28 In both studies, pain was 
assessed using visual analogue scales (VAS) and statistical 
analysis was conducted in patients with a VAS score  30. 
This score was considered to be the point at which patients 
with little or no bodily pain was distinguishable from those 
with notable pain. Based upon these criteria, 44% of patients 
were identified in the intent to treat (ITT) group. Results 
of the analysis showed a significant decrease in overall 
VAS score for the duloxetine treated patients compared 
to placebo (mean change from baseline 48.7% vs 31.3%; 
P  0.001). There was also a direct correlation between 
reduction in VAS score and improvement in CGI-I scores. 
Patients with a final CGI-I score of 1 (max. improvement) 
had a mean reduction of 77.4% in total VAS score. Likewise, 
this was shown in the relationship between VAS score and 
PGI-I score, with patients having a final PGI-I score of 1 
(maximum improvement) having a mean reduction in VAS 
score of 76.4%. Given that GAD patients with pain have 
more severe symptoms, this analysis shows that duloxetine 
can deliver significant reductions in pain in patients with 
anxiety.
Another meta-analysis study assessed duloxetine’s 
use in elderly patients with GAD. Clearly, pharmaco-
therapy in this population carries with it treatment concerns 
including polypharmacy, changes in drug metabolism, 
and other geriatric conditions such as Alzheimers disease. 
Davidson et al33 pooled data from four studies that were 
discussed previously.27–30 Out of the 1491 patients, data were 
taken from patients over 65 years of age, where 45 patients in 
the duloxetine group and 28 in the placebo group were found 
(73 patients in total equaling 4.9% of sample). All patient 
data were used to evaluate safety, and patients who completed International Journal of General Medicine 2009:2 159
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at least one post baseline measurement were included in the 
efficacy analysis. The analysis showed that a significant 
reduction in HAM-A total score for patients treated with 
duloxetine occurred compared to placebo (10.1 vs 5.9; 
P = 0.029). Other significant improvements were noted for 
the HAM-A-psychic factor, HADS anxiety and depression 
scales. However, significant differences between CGI-I or 
PGI-I scores compared to placebo, or rates of remission 
and sustained improvement were not found (24% vs 7%, 
P = 0.053 and 62% vs 36%, P = 0.05, respectively). The 
study authors concluded the lack of statistical significance 
was likely due to the relatively small number of study subjects 
involved in the analysis.
Safety and tolerability
In general, duloxetine was safe and well tolerated with AEs 
being mild to moderate in severity. The most common AE 
was nausea (experienced by about 30% to 40% of duloxetine 
patients) and it was the most frequent reason for study 
discontinuation due to an AE. Other AEs that occurred more 
often than placebo were constipation, dry mouth, somno-
lence, decreased appetite, insomnia, decreased libido, and 
yawning, although these were regarded as mild and occurred 
at a relatively low rate.27–31 Discontinuation rates due to all 
AEs for duloxetine patients varied from 2.4% to 20.2%.27,28
Serious adverse events (SAEs) occurred at a low 
frequency, and consisted of upper abdominal pain, vom-
iting, renal cell carcinoma, alcoholism, depression, self-
mutilation,29anxiety, atrial fibrillation, back pain, chest pain, 
migraine,28 myocardial infarction, erysipelas,27 bronchitis, 
diarrhea, worsening of GAD, and a ruptured tendon.31 There 
was no significant difference in SAEs between active and 
placebo groups. There were 2 fatalities (cerebral hemorrhage 
and suicide), although these were determined to be unrelated 
to study drug.31 Discontinuation emergent adverse events 
occurred at a rate of 19.9% to 22.1%, dizziness being the 
most prominent.27–31
In the analysis examining duloxetine in GAD patients 
with significant pain symptoms, safety and tolerability 
were not analyzed statistically. For duloxetine use in the 
elderly population, adverse event rates were similar to those 
observed among the general population.33 Nausea was the 
most experienced AE, 30% of duloxetine-treated patients 
experiencing nausea vs 7.1% for placebo (P = 0.023). 
In addition, duloxetine-treated patients lost more weight 
than the placebo group (-1.1 kg vs 0.0 kg, P = 0.018). There 
were no other significant differences between the 2 groups in 
AEs or reported lab values. A list of AEs and their frequency 
is shown in Table 3.
Discussion
Duloxetine is approved for treatment for GAD in doses of 
30 mg to 120 mg daily. Studies have indicated that duloxetine 
can reduce GAD symptoms. Duloxetine showed significant 
reductions in HAM-A scores and other measures of GAD. 
Duloxetine also appears to be relatively well tolerated with 
AEs being relatively mild and comparable to other those for 
reuptake inhibitors. Interestingly, in one study,30 a 20 mg 
dose of duloxetine appeared to offer similar efficacy to the 
higher doses used (60 to 120 mg). It may be worthwhile 
conducting a dose-response study to determine if GAD could 
be successfully treated with duloxetine at doses lower than 
those currently used, or for clinicians to initiate treatment at 
20 mg daily for 4 to 6 weeks before titrating to higher doses. 
This may help improve patient adherence by reducing the 
frequency and severity of AEs.
Only one noninferiority comparator study (against 
venlafaxine XR) has been done, therefore it is difficult to 
assess whether duloxetine is a more appropriate treatment 
option other compared with more established and less 
costly options. Allgulander et al34 analyzed duloxetine vs 
venlafaxine using data from 2 previous studies.29,30 This 
analysis found a HAM-A score decrease of 3.8 for duloxetine 
over placebo and of 3.6 for venlafaxine over placebo, which 
confirmed that duloxetine met criteria for noninferiority 
against venlafaxine XR. In addition to the efficacy outcome, it 
was observed that there was no significant difference between 
the duloxetine and venlafaxine XR groups in the number of 
patients who discontinued the study because of AEs, or in 
rate of discontinuation for any specific AE. Both medica-
tions had similar tolerability and safety profiles, except for 
nausea and yawning which occurred at significantly higher 
rates in duloxetine-treated patients (nausea rates were 26.9% 
for duloxetine and 20.1% for venlafaxine XR [P  0.05], 
yawning data not reported).
First-line treatment options available for treating GAD 
involve the use of SSRIs, SNRIs, benzodiazepines, and 
buspirone.2 Benzodiazepines are particularly effective 
anxiolytics; however, their lack of antidepressant effect and 
side effect profile make them undesirable for long-term use. 
Buspirone has good anxiolytic properties, but its negligible 
antidepressant effect makes it unsuitable for treating the 
comorbid depression that is highly prevalent in the GAD 
patient population. Antidepressants such as the SSRI par-
oxetine, and the SNRI venlafaxine have been shown to be International Journal of General Medicine 2009:2 160
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both effective anxiolytics and antidepressants, making them 
good options for the GAD patient.35 Duloxetine, being a 
SNRI, is one more option at hand from the array of medica-
tions available in the SSRI/SNRI class. However, at this 
time it should be noted there are no direct comparator stud-
ies between these different drug classes, thus it is difficult 
to ascertain the superiority of one treatment over another. 
Whether clinicians choose to begin treating GAD with an 
SNRI, SSRI, or other class of medication will ultimately 
come down to patient history, tolerability to the medication, 
clinician experiences, and cost.36
It should be noted that all five efficacy studies were 
sponsored by Eli Lilly, who developed and market duloxetine 
(Cymbalta®).
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